Efficacy of tocilizumab in severe COVID-19 infection: a retrospective observational study.
Aristotle University of Thessaloniki · 02.01.2025
DOI: 10.26262/abj.v7i1.10416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 02.01.2025. Verfasst von Maria Sarigianni.
Abstract (Originalsprache)
Introduction
Aim of the present study was to evaluate the efficacy of adding tocilizumab (TCZ) to standard care in improving survival or the requirement of mechanical ventilation (MV) at 60-day follow-up.
Methods
It is a retrospective observational study of all hospitalized patients with severe COVID-19 infection who received TCZ in addition to standard care (TCZ group) and were compared with standard care alone (control group).
Results
A total of 39 patients were included in the study (mean age 65±11 years), 20 patients in the TCZ group and 19 in the control group. There was no difference in regards to age, gender, comorbidities and concomitant medications (p0.1). However, more patients in the TCZ group required high flow nasal oxygen supplementation [14 (70%)] compared with the control group [6 (32%)] (p=0.016). More patients died at 60 days in the TCZ group [18 (90%) vs 9 (47%), respectively, p=0.004] and less were discharged [2 (10%) vs 10 (53%), respectively, p=0.004] compared with the control group. The occurrence of death or MV at 14 days did not differ between the two groups (p0.1). The rate of adverse events (infection, sepsis, septic shock, and pulmonary embolism) occurrence did not differ between the two groups (p0.05).
Conclusions
Tocilizumab added to standard care in patients with severe COVID-19 respiratory infection could lead to short-term clinical improvement but did not improve survival at 60 days. More studies are needed to establish the clinical efficacy of TCZ and to define in which disease stage could be beneficial.
Schlagwörter
Zitieren
APA
Sarigianni, M. (2025). Efficacy of tocilizumab in severe COVID-19 infection: a retrospective observational study. Aristotle University of Thessaloniki. https://doi.org/10.26262/abj.v7i1.10416
Vancouver
Sarigianni M. Efficacy of tocilizumab in severe COVID-19 infection: a retrospective observational study. Aristotle University of Thessaloniki. 2025. doi:10.26262/abj.v7i1.10416
BibTeX
@article{Sarigianni2025,
author = {Sarigianni, Maria},
title = {Efficacy of tocilizumab in severe COVID-19 infection: a retrospective observational study},
journal = {Aristotle University of Thessaloniki},
year = {2025},
doi = {10.26262/abj.v7i1.10416}
}
EUVIMED